RUNX2 and cancer: In this review, we focus mainly on critical and recent research developments, including RUNX2’s oncogenic activities, by summarizing and integrating the findings on somatic mutations of RUNX2, transcriptomic studies, clinical information, and discoveries about how the RUNX2-induced signaling pathway modulates malignant progression in cancer.